Lucid Diagnostics Inc. (LUCD), Thursday announced a positive outcome from the first prospective clinical validation study of the company's EsoGuard Esophageal DNA test for esophageal precancer detection in a screening population.
The study outcome revealed that EsoGuard demonstrated sensitivity and negative predictive value, including unprecedented performance of a molecular diagnostic test in detecting a precancer.
Victoria Lee, Lucid's Chief Medical Officer said, "The clinical validity and clinical utility data, coupled with multiple national society guidelines and consensus statements supporting EsoGuard esophageal precancer detection, provides a strong foundation of critical evidence needed to support broad EsoGuard medical policy coverage and a line of sight to CMS coverage, in particular."
Currently, Lucid's stock is slipping 6.3 percent, to $1.04 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.